|Articles|December 9, 2022

A Changing Horizon for Digital Health Technologies

Author(s)Cognizant

Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.